Limited Competition: Revisions to Add Phase 2 Clinical Trials Program to Experimental Therapeutics Clinical Trials Network (ETCTN)(UM1)

The summary for the Limited Competition: Revisions to Add Phase 2 Clinical Trials Program to Experimental Therapeutics Clinical Trials Network (ETCTN)(UM1) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Limited Competition: Revisions to Add Phase 2 Clinical Trials Program to Experimental Therapeutics Clinical Trials Network (ETCTN)(UM1): The purpose of this Funding Opportunity Announcement (FOA) is to enhance the NCI-supported early development of experimental cancer therapeutics by merging the Phase 2 clinical trials program with the Experimental Therapeutics Clinical Trials Network (ETCTN, funded through RFA-CA-13-006) that is currently focused on Phase 1 clinical trials.

The FOA invites revision applications from ETCTN UM1 awardees to expand the scope of activities by adding capabilities to conduct Phase 2 clinical trials. The goal is to integrate Phase 2 infrastructure and expertise to create a unified network for an efficient and comprehensive conduct of early clinical trials. This integration of the Phase 2 capabilities into the new ETCTN structure will allow for more seamless advancement of experimental agents through early stages of development. Ultimately, the expected increased efficiency of clinical trial management is expected to accelerate the delivery of new cancer therapies to the public.

Federal Grant Title:	Limited Competition: Revisions to Add Phase 2 Clinical Trials Program to Experimental Therapeutics Clinical Trials Network (ETCTN)(UM1)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-CA-15-501
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.395
CFDA Descriptions:	Cancer Treatment Research
Current Application Deadline:	Jun 19, 2015
Original Application Deadline:	Jun 19, 2015
Posted Date:	Mar 23, 2015
Creation Date:	Mar 23, 2015
Archive Date:	Jul 20, 2015
Total Program Funding:	$7,200,000
Maximum Federal Grant Award:	$560,000
Minimum Federal Grant Award:	none
Expected Number of Awards:	10
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Public and State controlled institutions of higher education
Private institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following:
Only current ETCTN UM1 awardees may submit revision applications invited by this FOA (including Canadian recipients of the ETCTN award). See full announcement for full details.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-15-501.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Mino...; • Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical...; • Single Source: Pediatric Early Phase Clinical Trials Network (PEP-CTN; UM1 Clinical Trial ...; • Assay development and screening for discovery of chemical probes, drugs or immunomodulator...; • Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed); • Breast and Prostate Cancer Data Quality and Patterns of Care Study; • Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults; • National Cooperative Drug Discovery Groups for Cancer
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...